AxoGen, Inc. (AXGN) vs Palvella Therapeutics, Inc. (PVLA)
A side-by-side comparison of AxoGen, Inc. and Palvella Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AXGN
AxoGen, Inc.
$36.31HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PVLA
Palvella Therapeutics, Inc.
$128.00HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — AXGN vs PVLA
growth of $100 · dividends reinvested · last 2yAXGN +153.7% (+59.3%/yr)PVLA +677.4% (+178.8%/yr)PVLA compounded faster over this window
AXGN PVLA
AXGN vs PVLA: by the numbers
- •AXGN is the larger company ($1.95B vs $1.84B market cap).
- •Both run net losses; PVLA's is the smaller (0.00% vs -13.36% net margin).
Metrics side by side
Valuation
| Metric | AXGN | PVLA |
|---|---|---|
| Forward P/E | 82.06 | N/A |
| P/S ratio | 7.77 | N/A |
| P/B ratio | 7.62 | 8.47 |
| FCF yield | 0.13% | N/A |
Profitability
| Metric | AXGN | PVLA |
|---|---|---|
| Gross margin | 74.56% | 0.00% |
| Operating margin | -5.12% | 0.00% |
| Net margin | -13.36% | 0.00% |
| ROE | -13.09% | -28.45% |
| ROIC | -4.68% | -23.90% |
Growth (annualized)
| Metric | AXGN | PVLA |
|---|---|---|
| Revenue CAGR (5Y) | 13.99% | N/A |
| Total return CAGR (5Y) | 19.40% | N/A |
Go deeper
Dig into the metrics
AxoGen ROEPalvella Therapeutics ROEAxoGen operating marginPalvella Therapeutics operating marginAxoGen revenue growthPalvella Therapeutics revenue growthAxoGen free cash flowPalvella Therapeutics free cash flow
AxoGen & Palvella Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.